{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:51:26Z","timestamp":1781625086711,"version":"3.54.5"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.mehy.2019.109544","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T11:36:31Z","timestamp":1577964991000},"page":"109544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities"],"prefix":"10.1016","volume":"137","author":[{"given":"Muhammed Khairujjaman","family":"Mazumder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupom","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvasish","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109544_b0005","series-title":"An essay on the shaking palsy","author":"Parkinson","year":"1817"},{"issue":"6","key":"10.1016\/j.mehy.2019.109544_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009282","article-title":"Motor control abnormalities in Parkinson's disease","volume":"2","author":"Mazzoni","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9996","key":"10.1016\/j.mehy.2019.109544_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2019.109544_b0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","article-title":"Parkinson disease: from pathology to molecular disease mechanisms","volume":"62","author":"Dexter","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.mehy.2019.109544_b0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mehy.2019.109544_b0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.mehy.2019.109544_b0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mehy.2019.109544_b0040","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/npjparkd.2016.1","article-title":"Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson\u2019s disease","volume":"2","author":"Perez-Lloret","year":"2016","journal-title":"NPJ Parkinson's Dis"},{"issue":"4","key":"10.1016\/j.mehy.2019.109544_b0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1023\/B:JOBB.0000041772.74810.92","article-title":"Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment","volume":"36","author":"Beal","year":"2004","journal-title":"J Bioenergy Biomembr"},{"issue":"5","key":"10.1016\/j.mehy.2019.109544_b0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ng1769","article-title":"High levels of mitochondrial DNA deletions in Substantia nigra neurons in aging and Parkinson disease","volume":"38","author":"Bender","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.mehy.2019.109544_b0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0072-9752(07)83024-7","article-title":"Oxidative stress and Parkinson\u2019s disease","volume":"83","author":"Jenner","year":"2007","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"10.1016\/j.mehy.2019.109544_b0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","article-title":"Multiple hit hypotheses for dopamine neuron loss in Parkinson\u2019s disease","volume":"30","author":"Sulzer","year":"2007","journal-title":"Trends Neurosci"},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2019.109544_b0065","first-page":"S3","article-title":"What causes cell death in Parkinson\u2019s disease?","volume":"64","author":"Gupta","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2019.109544_b0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1196\/annals.1427.023","article-title":"Oxidative stress in Parkinson\u2019s disease: a mechanism of pathogenic and therapeutic significance","volume":"1147","author":"Zhou","year":"2008","journal-title":"Ann NY Acad Sci"},{"issue":"4","key":"10.1016\/j.mehy.2019.109544_b0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.mehy.2019.109544_b0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nurt.2010.05.014","article-title":"Microglial activation and chronic neurodegeneration","volume":"7","author":"Lull","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.mehy.2019.109544_b0085","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.mehy.2019.109544_b0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pneurobio.2011.06.005","article-title":"L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson\u2019s disease?","volume":"94","author":"Lipski","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.mehy.2019.109544_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJM197001012820107","article-title":"Aromatic amino acids and modification of Parkinsonism","volume":"282","author":"Cotzias","year":"1967","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.mehy.2019.109544_b0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ncl.2009.04.004","article-title":"Etiology and pathogenesis of Parkinson disease","volume":"27","author":"Schapira","year":"2009","journal-title":"Neurol Clin"},{"issue":"Suppl. 4","key":"10.1016\/j.mehy.2019.109544_b0105","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1353-8020(09)70834-X","article-title":"Neuroprotection in Parkinson\u2019s disease","volume":"15","author":"Schapira","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"24","key":"10.1016\/j.mehy.2019.109544_b0110","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson\u2019s disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mehy.2019.109544_b0115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.mehy.2019.109544_b0120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/mol.106.024703","article-title":"A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition","volume":"70","author":"Zafar","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2019.109544_b0125","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1002\/mds.22146","article-title":"The clinical relevance of levodopa toxicity in the treatment of Parkinson\u2019s disease","volume":"23","author":"Schapira","year":"2008","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.mehy.2019.109544_b0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0197-0186(02)00075-X","article-title":"Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity","volume":"42","author":"Blessing","year":"2003","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.mehy.2019.109544_b0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease","volume":"75","author":"M\u00fcller","year":"2015","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.mehy.2019.109544_b0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/cns.12113","article-title":"\u03b2-phenethylamine \u2013 a phenylalanine derivate in brain \u2013 contributes to oxidative stress by inhibiting mitochondrial complexes and DT-diaphorase: an in silico study","volume":"19","author":"Mazumder","year":"2013","journal-title":"CNS Neurosci Therap"},{"key":"10.1016\/j.mehy.2019.109544_b0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mehy.2018.06.009","article-title":"Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease","volume":"117","author":"Mazumder","year":"2018","journal-title":"Med Hypotheses"},{"issue":"2","key":"10.1016\/j.mehy.2019.109544_b0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mehy.2012.05.008","article-title":"L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients","volume":"79","author":"Borah","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2019.109544_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.expneurol.2007.05.002","article-title":"The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates","volume":"208","author":"Zubair","year":"2007","journal-title":"Exp Neurol"},{"issue":"12","key":"10.1016\/j.mehy.2019.109544_b0160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.mehy.2019.109544_b0165","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00044-015-1472-z","article-title":"Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: an in silico approach","volume":"25","author":"Mazumder","year":"2016","journal-title":"Med Chem Res"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2019.109544_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2015.03.046","article-title":"Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism","volume":"353","author":"Park","year":"2015","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.mehy.2019.109544_b0175","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1212\/WNL.39.8.1109","article-title":"Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson\u2019s disease","volume":"39","author":"Golbe","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archneur.1991.00530130039017","article-title":"Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson\u2019s disease: experience in 26 patients receiving combined therapy for 26 months","volume":"48","author":"Elizan","year":"1991","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/002383099200500105","article-title":"Side effects of selegiline (eldepryl)","volume":"5","author":"Waters","year":"1992","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.mehy.2019.109544_b0190","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jama.1994.03510370037029","article-title":"A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease","volume":"271","author":"Knapp","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2019.109544_b0195","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2019.109544_b0200","first-page":"45","article-title":"The tolerability and safety of cholinesterase inhibitors in the treatment of dementia","volume":"127","author":"Inglis","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"issue":"11","key":"10.1016\/j.mehy.2019.109544_b0205","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00002018-200326110-00001","article-title":"Tolcapone-related liver dysfunction: implications for use in Parkinson\u2019s disease therapy","volume":"26","author":"Borges","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.mehy.2019.109544_b0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-381326-8.00007-7","article-title":"Toxicology and safety of COMT inhibitors","volume":"95","author":"Haasio","year":"2010","journal-title":"Int Rev Neurobiol"},{"issue":"12","key":"10.1016\/j.mehy.2019.109544_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2019.109544_b0220","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1096\/fj.03-0057fje","article-title":"Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia","volume":"17","author":"Lee","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2019.109544_b0225","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00213-004-2104-3","article-title":"Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine","volume":"179","author":"Haskell","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.mehy.2019.109544_b0230","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1179\/1743132813Y.0000000293","article-title":"Resveratrol treatment has neuroprotective effects and prevents cognitive impairment after chronic cerebral hypoperfusion","volume":"36","author":"Anastacio","year":"2014","journal-title":"Neurol Res"},{"issue":"6","key":"10.1016\/j.mehy.2019.109544_b0235","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1515\/revneuro-2016-0004","article-title":"Phytochemicals as future drugs for Parkinson's disease: a comprehensive review","volume":"27","author":"Shahpiri","year":"2016","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.mehy.2019.109544_b0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imu.2016.09.002","article-title":"Review on potential phytocompounds in drug development for Parkinson disease: a pharmacoinformatic approach","volume":"5","author":"Vijayakumar","year":"2015","journal-title":"Inf Med Unlocked"},{"key":"10.1016\/j.mehy.2019.109544_b0245","series-title":"Discovery and development of anti-inflammatory agents from natural products, natural product drug discovery","first-page":"241","article-title":"Therapeutic implications of anti-inflammatory natural products in Alzheimer\u2019s disease","author":"Deb","year":"2019"},{"issue":"2","key":"10.1016\/j.mehy.2019.109544_b0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nrleng.2016.04.014","article-title":"Neuroprotective effects of phytochemicals on dopaminergic neuron culturesEfecto neuroprotector de fitoqu\u00edmicos en cultivo de neuronas dopamin\u00e9rgicas","volume":"34","author":"Sandoval-Avila","year":"2019","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"10.1016\/j.mehy.2019.109544_b0255","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mehy.2014.09.021","article-title":"Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis","volume":"83","author":"Mazumder","year":"2014","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2019.109544_b0260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ibror.2019.05.003","article-title":"An in silico investigation on the inhibitory potential of the constituents of Pomegranate juice on antioxidant defense mechanism: relevance to neurodegenerative diseases","volume":"6","author":"Mazumder","year":"2019","journal-title":"IBRO Rep"},{"key":"10.1016\/j.mehy.2019.109544_b0265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mehy.2019.02.035","article-title":"Tea polyphenols as multi-target therapeutics for Alzheimer\u2019s disease: an in silico study","volume":"125","author":"Mazumder","year":"2019","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2019.109544_b0270","series-title":"Monoamine oxidases \u2014 new vistas advances in biochemistry and psychopharmacology, vol. 5","first-page":"393","article-title":"Some puzzling pharmacological effects of monoamine oxidase inhibitors","author":"Knoll","year":"1972"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00002826-199901000-00005","article-title":"Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease","volume":"22","author":"Napolitano","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2019.109544_b0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00002093-199809000-00017","article-title":"Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities","volume":"12","author":"Nordberg","year":"1998","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.mehy.2019.109544_b0285","series-title":"Neuroprotective natural products: clinical aspects and mode of action","article-title":"Neuroprotective effect of Ayurvedic preparations and natural products on Parkinson\u2019s disease","author":"Borah","year":"2017"},{"issue":"10","key":"10.1016\/j.mehy.2019.109544_b0290","doi-asserted-by":"crossref","first-page":"473","DOI":"10.6026\/97320630004473","article-title":"Computational analysis of the activity of pongachalcone I against highly resistant bacteria Pseudomonas putida","volume":"4","author":"Paul","year":"2010","journal-title":"Bioinformation"},{"key":"10.1016\/j.mehy.2019.109544_b0295","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.lfs.2006.02.019","article-title":"Acteoside and its aglycones protect primary cultures of rat cortical cells from glutamate-induced excitotoxicity","volume":"79","author":"Koo","year":"2006","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.mehy.2019.109544_b0300","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3892\/etm.2017.4254","article-title":"Neuroprotective effects of phenylethanoid glycosides in an in vitro model of Alzheimer's disease","volume":"13","author":"Yang","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.mehy.2019.109544_b0305","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1211\/0022357023501","article-title":"Acteoside protects endothelial cells against free radical-induced oxidative stress","volume":"56","author":"Chiou","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.mehy.2019.109544_b0310","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1055\/s-0030-1249775","article-title":"Inhibitory effect of acteoside isolated from Cistanche tubulosa on chemical mediator release and inflammatory cytokine production by RBL-2H3 and KU812 cells","volume":"76","author":"Yamada","year":"2010","journal-title":"Planta Med"},{"key":"10.1016\/j.mehy.2019.109544_b0315","first-page":"2956","article-title":"Effect of acteoside on learning and memory impairment induced by scopolamine in mice","volume":"37","author":"Lin","year":"2012","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.mehy.2019.109544_b0320","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.taap.2015.04.004","article-title":"Effects of acteoside on lipopolysaccharide-induced inflammation in acute lung injury via regulation of NF-\u03baB pathway in vivo and in vitro","volume":"285","author":"Jing","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2019.109544_b0325","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/ijms18040895","article-title":"Acteoside and isoacteoside protect amyloid \u03b2 peptide induced cytotoxicity, cognitive deficit and neurochemical disturbances in vitro and in vivo","volume":"18","author":"Shiao","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2019.109544_b0330","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6241017","article-title":"Rutin as a potent antioxidant: implications for neurodegenerative disorders","author":"Enogieru","year":"2018","journal-title":"Oxid Med Cell Longevity"},{"issue":"25\u201326","key":"10.1016\/j.mehy.2019.109544_b0335","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.lfs.2011.09.023","article-title":"Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells","volume":"89","author":"Jim\u00e9nez-Aliaga","year":"2011","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0394632015613039","article-title":"Protective effects of quercetin glycosides, rutin, and isoquercetrin against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat pheochromocytoma (PC-12) cells","volume":"29","author":"Magalingam","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.mehy.2019.109544_b0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cbi.2017.07.004","article-title":"The flavonoid rutin modulates microglial\/macrophage activation to a CD150\/CD206 M2 phenotype","volume":"274","author":"Bispo da Silva","year":"2017","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12640-011-9295-2","article-title":"Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson\u2019s disease","volume":"22","author":"Khan","year":"2012","journal-title":"Neurotoxicol Res"},{"issue":"6","key":"10.1016\/j.mehy.2019.109544_b0355","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/jmf.2014.3292","article-title":"The n-butanol fraction and rutin from tartary buckwheat improve cognition and memory in an in vivo model of amyloid-\u03b2-induced Alzheimer\u2019s disease","volume":"18","author":"Choi","year":"2015","journal-title":"J Med Food"},{"key":"10.1016\/j.mehy.2019.109544_b0360","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/DDDT.S103511","article-title":"Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats","volume":"11","author":"Ramalingayya","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.mehy.2019.109544_b0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.intimp.2009.12.004","article-title":"Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related mapk\/nf-kappab signaling pathways in N9 microglia induced by lipopolysaccharide","volume":"10","author":"Zhang","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.mehy.2019.109544_b0370","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.pbb.2008.09.010","article-title":"Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in alzheimer\u2019s disease","volume":"91","author":"Ahmed","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"10.1016\/j.mehy.2019.109544_b0375","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/molecules21081022","article-title":"Enhanced cognitive effects of demethoxycurcumin, a natural derivative of curcumin on scopolamine-induced memory impairment in mice","volume":"21","author":"Lim","year":"2016","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.mehy.2019.109544_b0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12906-017-1720-5","article-title":"Neuroprotective effect of demethoxycurcumin, a natural derivative of curcumin on rotenone induced neurotoxicity in SH-SY 5Y neuroblastoma cells","volume":"17","author":"Ramkumar","year":"2017","journal-title":"BMC Complement Altern Med"},{"issue":"53","key":"10.1016\/j.mehy.2019.109544_b0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/pm.pm_113_17","article-title":"Demethoxycurcumin, a natural derivative of curcumin abrogates rotenone-induced dopamine depletion and motor deficits by its antioxidative and anti-inflammatory properties in parkinsonian rats","volume":"14","author":"Ramkumar","year":"2018","journal-title":"Pharmacogn Mag"},{"key":"10.1016\/j.mehy.2019.109544_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2741\/e841","article-title":"Demethoxycurcumin ameliorates rotenone-induced toxicity in rats","volume":"11","author":"Ramkumar","year":"2019","journal-title":"Front Biosci (Elite Ed)"},{"key":"10.1016\/j.mehy.2019.109544_b0395","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2005.01.031","article-title":"Cognitive correlates of alterations in acetylcholinesterase in Alzheimer\u2019s disease","volume":"380","author":"Bohnen","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2019.109544_b0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuint.2016.10.001","article-title":"Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease","volume":"101","author":"Bhattacharjee","year":"2016","journal-title":"Neurochem Int"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719312289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719312289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:19:20Z","timestamp":1759691960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719312289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":80,"alternative-id":["S0306987719312289"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109544","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109544"}}